Postoperative growth hormone dynamics in clinically nonfunctioning pituitary adenoma.

Kobayashi N, Yamaguchi-Okada M, Horiguchi K, Fukuhara N, Nishioka H, Yamada S

Endocrine journal15 Jun 2018Cited by 6 (Europe PMC)

PMID29910227DOI10.1507/endocrj.ej17-0536PepBankPUB-29910227

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

01HumanNot a test of GHRP-2 aloneObservational studyOther
In 119 patients with non-functioning pituitary adenoma after transsphenoidal surgery, 94 (79.0%) had peak GH below 9.0 ng/mL on the GHRP2 test and were diagnosed with severe GH deficiency.
In plain wordsAfter pituitary surgery, most patients had severe growth hormone deficiency on a GHRP2 test.
Peptide
GHRP-2
Outcome
Not applicableSevere GHD on GHRP2 test after surgery
Study
n = 119
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Of 119 patients analyzed, 94 (79.0%) had peak GH levels less than 9.0 ng/mL and were diagnosed with severe GHD (sGHD) immediately after surgery.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we analyzed patients with NFPAs that underwent transsphenoidal surgery. Postoperatively, GH secretion was evaluated in response to GH-releasing peptide-2 (GHRP2) infusion.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2991022701
02HumanNot a test of GHRP-2 aloneObservational studyOther
Of 94 patients with severe GH deficiency after surgery, 27 (28.7%) recovered within 1-2 years.
In plain wordsMore than a quarter of patients with severe growth hormone deficiency after surgery recovered within 1-2 years.
Peptide
GHRP-2
Outcome
Not applicableRecovery from severe GHD within 1-2 years
Study
n = 94
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Of those patients, 27 (28.7%) recovered from sGHD within 1-2 years after surgery.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we analyzed patients with NFPAs that underwent transsphenoidal surgery. Postoperatively, GH secretion was evaluated in response to GH-releasing peptide-2 (GHRP2) infusion.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2991022702
03HumanNot a test of GHRP-2 aloneObservational studyOther
In univariate analyses, sGHD recovery was more frequent in younger patients, after a single primary surgery, without other anterior hormone deficiency, and with cystic adenoma or normal IGF1 SD-S.
In plain wordsRecovery from severe growth hormone deficiency was more likely in younger patients and in those with fewer other hormone problems.
Peptide
GHRP-2
Outcome
Not applicableUnivariate predictors of sGHD recovery
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Univariate analyses confirmed that sGHD recovery improved significantly in patients that were younger, had only undergone a single primary surgery, had not had anterior hormone deficiency except GH, and had cystic adenoma or normal insulin-like growth factor-1 (IGF1) standard deviation score (SD-S)…
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we analyzed patients with NFPAs that underwent transsphenoidal surgery. Postoperatively, GH secretion was evaluated in response to GH-releasing peptide-2 (GHRP2) infusion.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2991022703
04HumanNot a test of GHRP-2 aloneObservational studyOther
In multivariate analyses, younger age and absence of hormone replacement therapy predicted sGHD recovery within 1-2 years after surgery.
In plain wordsYounger age and no hormone replacement therapy predicted recovery from growth hormone deficiency after surgery.
Peptide
GHRP-2
Outcome
Not applicableMultivariate predictors of sGHD recovery
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Multivariate analyses confirmed that younger age and absence of hormone replacement therapy significantly predicted sGHD recovery within 1-2 years after surgery.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, we analyzed patients with NFPAs that underwent transsphenoidal surgery. Postoperatively, GH secretion was evaluated in response to GH-releasing peptide-2 (GHRP2) infusion.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2991022704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.